Skip to main content
NCBI home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2024 Sep 18;15(9):682. doi: 10.1038/s41419-024-07070-1

Retinal prolactin isoform PRLΔE1 sustains rod disease in inherited retinal degenerations

Raghavi Sudharsan 1,✉, Jennifer Kwok 1, Malgorzata Swider 2, Alexander Sumaroka 2, Gustavo D Aguirre 1, Artur V Cideciyan 2, William A Beltran 1,✉
PMCID: PMC11410941  PMID: 39294136

Abstract

PRLΔE1, a retina-specific isoform of prolactin, is expressed in multiple and diverse forms of canine inherited retinal degeneration (IRD). We find that while PRLΔE1 expression in rods is not associated with the initial phase of disease characterized by acute photoreceptor cell death, it is associated with the protracted phase of slow cell loss. Restoration of photoreceptors to a healthy state by gene-specific replacement therapy of individual IRDs successfully suppresses PRLΔE1 expression. Moreover, short-term PRLΔE1 silencing using shRNA results in preservation of outer nuclear layer thickness, suggesting PRLΔE1 drives retinal disease. However, longer-term observations reveal off-target toxic effects of the PRLΔE1 shRNA, precluding determination of its full therapeutic potential. Future research efforts aimed at enhancing the safety and specificity of PRLΔE1-targeting strategies may identify a potential universal intervention strategy for sustaining photoreceptors during the prolonged phase of multiple IRDs.

Subject terms: Retina, Neurodegeneration

Introduction

Prolactin (PRL) is a pleiotropic hormone that contributes to multiple physiologic and homeostatic functions in the body including maturation of mammary glands and initiation of lactation, metabolic regulation, angiogenesis, immunomodulation, neuroprotection, and neurogenesis [1–6]. Full-length PRL activates the JAK/STAT pathway through its transmembrane receptor PRL-R, which is expressed on multiple cell types [7]. PRL plays a protective role in light-induced retinal degeneration and in diabetic retinopathy [3, 8–12]. Its anti-apoptotic and antioxidant effects promote survival of both the photoreceptors (PR) and the retinal pigment epithelium (RPE) [10, 13, 14]. PRL modulates neurotrophin signaling from glial cells to protect PRs from light-induced damage in the rodent retina [10]. Clinically, elevated circulating levels of PRL have been associated with a reduced risk of proliferative diabetic retinopathy in diabetic patients, largely due to the antiangiogenic properties of vasoinhibins, a family of bioactive peptides generated from the N-terminus of PRL by proteolytic cleavage. These peptides are currently being investigated as a therapeutic target to regulate ocular angiogenesis and prevent disease progression in diabetic retinopathy and diabetic macular edema [9, 15–18].

Although mainly synthesized by lactotrophic cells of the anterior pituitary gland, PRL is also expressed in other tissues [19, 20], including normal retinas from rats, green monkeys, and baboons [15, 21, 22]. Notably, we previously identified PRLΔE1, a novel isoform of PRL that lacks the first exon, expressed in the retinas of two non-allelic, naturally occurring canine models of early-onset inherited retinal degeneration (IRD), PDE6β-RCD1 and RPGR-XLPRA2 [23]. In these two models, a large number of PRs die acutely between 5 and 7 weeks of age, marking the early phase of disease [24, 25]. Immediately after this burst of cell death, PRLΔE1 expression is induced in the remaining rods and increases through the protracted phase of disease/degeneration, even as the rate of cell death declines [23]. Expression of PRLΔE1 is not observed in healthy young or adult dog retinas. However, this PRL isoform is found in the aged human retina [23].

In the current study, we have further examined the expression of PRLΔE1 in two additional canine models of IRD. We demonstrate that PRLΔE1 expression correlates with protracted RD and not acute PR cell death. We also provide preliminary insights into the function of PRLΔE1 in IRD and present evidence that PRLΔE1 is a viable therapeutic target for promoting PR cell survival.

Results

Rod-specific expression of PRLΔE1 in canine IRD with protracted PR degeneration

In our earlier publication [23], we described the expression of PRLΔE1 transcript in the PRs in PDE6β-RCD1 [26–28] and RPGR-XLPRA2 [24, 29] dogs. To determine whether PRLΔE1 expression is common to other forms of IRD, we examined additional canine models of IRD. We now show that this shorter PRL transcript is also expressed in RPGR-XLPRA1 (X-Linked Progressive Retinal Atrophy 1, caused by a five-nucleotide deletion in the RPGR exon ORF15) [29, 30] (Fig. 1A) and NPHP5-LCA (Leber Congenital Amaurosis, caused by a single nucleotide insertion in exon 10 of the IQCB1/NPHP5 gene) [31, 32] (Fig. 1B). Both diseases affect rods and cones, however, with varying age of onset and disease severity. In the rapidly degenerating NPHP5-LCA model, PRLΔE1 transcript was detected at 14 weeks of age. This time point is characterized by early stages of PR loss and moderate thinning of the ONL, consistent with the early phase of degeneration in this model [31]. In contrast, in the RPGR-XLPRA1 model, degenerative changes in the PR are observed before onset of cell death [33]. PRLΔE1 expression was observed starting at 26 weeks of age, which notably precedes the onset of noticeable PR loss. This early upregulation of PRLΔE1 expression prior to extensive PR cell death, indicates a potential role in the initial response to degenerative stress (Supplementary Fig. 1).

Fig. 1. PRLΔE1 expression in two additional canine models of inherited retinopathies and specifically in rods.

Fig. 1

Open in a new tab

PRLΔE1 mRNA identified by RNA in situ hybridization (magenta punctate staining, see black arrows) in the PRs in RPGR-XLPRA1 (A) and NPHP5-LCA (B), but not in CNGB3-ACHM3, a cone-specific disease (C). D1–D3 PRLΔE1 expression observed by RNA-ISH (white) only in the degenerating NPHP5-LCA ONL containing both rods and cones (D1, D3) and not in the adjacent cone-only ONL (D2, D3). Rhodopsin (RHO) staining for rods in green, Arrestin-3 (ARR3) staining for cones in red. Each panel represents observations from a single dog for the specified genotype. ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell layer.

To determine whether PR dysfunction without ongoing degeneration also induces PRLΔE1 expression, we examined a model of achromatopsia (CNGB3-ACHM3; mutation in Cyclic Nucleotide Gated Channel Subunit Beta 3), a disease with impaired cone function and structure, but no rod degeneration [34, 35]. Notably, in the absence of rod degeneration, retinal PRLΔE1 expression was not observed (Fig. 1C). Taken together, these results suggest that PRLΔE1 expression is associated with ongoing rod disease.

Identification of PR cell subclass (rods and/or cones) that express PRLΔE1 by RNA-in situ hybridization (RNA-ISH) within the outer nuclear layer (ONL, the cellular layer containing the PR cell bodies) is challenging due to the dense packing of rod and cone nuclei in this area. To determine the PR cell type that specifically expresses PRLΔE1, we took advantage of NPHP5-LCA retinas in which degeneration results in adjacent areas containing both rods and cones, or only cones. PRLΔE1 RNA-ISH staining was found in regions containing both PR cell types but not in cone-only areas (Fig. 1D), supporting rod-specific expression in degenerating retina. We further confirmed PRLΔE1 expression in rods, and not cones, using data from single-cell RNAseq analysis. (Supplementary Fig. 2). Thus, our study now firmly establishes the expression of PRLΔE1 in diseased rods in four different canine models of IRD.

PRLΔE1 expression colocalizes with areas of PR disease in RPGR-XLPRA carriers

To determine whether PRLΔE1 expression is restricted to degenerating rods, we examined its expression in the two RPGR-XLPRA carriers, XLPRA1 and XLPRA2. In female dogs with a single mutant copy of RPGR, random X-chromosome inactivation creates a mosaic of normal and mutant PRs [36]. Consequently, degeneration within the ONL occurs in patches that can be identified by opsin mislocalization to the PR cell bodies [36]. In both carrier retinas, PRLΔE1 expression overlapped with the patchy areas of degeneration identified by rhodopsin mislocalization and was not observed in the intervening patches with normal PRs (Fig. 2). Thus, PRLΔE1 expression is limited to mutant rods with active disease.

Fig. 2. PRLΔE1 expression overlaps with areas of PR degeneration in carriers of RPGR mutations.

Fig. 2

Open in a new tab

A1, B1 Retinal cellular layers identified by Hoechst staining of nuclei. Patchy areas of degeneration (white dashed boxes) resulting from random X-inactivation identified by rhodopsin mislocalization to PR cell bodies in A2 RPGR-XLPRA1 carriers (age: 24 weeks) and B2 RPGR-XLPRA2 (age: 24 weeks) carrier female dogs. A3, B3 PRLΔE1 transcript identified by RNA-ISH. A4, B4 Merged image show rhodopsin immunostaining in green and PRLΔE1 in magenta. Retinas from one RPGR-XPRA1 carrier dog and two RPGR-XLPRA2 carrier dogs were examined. ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell layer.

PRLΔE1 expression is not directly associated with acute PR cell death

To assess whether PRLΔE1 is associated with PR cell death, we examined its expression in the RHO-T4R dog, a large animal model of acute light-induced rod cell death caused by the T4R mutation in rhodopsin [37, 38]. In this model, rapid rod OS fragmentation occurs within hours of a one-minute exposure to white light at a corneal irradiance of 1 mW/cm2, and significant rod cell death is observed by extensive TUNEL labeling in the ONL at 24 h [39, 40]. However, no PRLΔE1 expression was detected at this time point (Fig. 3A). By 2 weeks post light exposure, the retina was reduced to one to two rows of PR with ongoing cell death, yet no PRLΔE1 was observed (Fig. 3B). In contrast, the PDE6β-RCD1 model, characterized by a protracted disease course, showed extensive PRLΔE1 expression at 14 weeks of age, a time when minimal TUNEL staining was present (Fig. 3C).

Fig. 3. PRLΔE1 expression is not associated with acute PR cell death in RHO-T4R ADRP but correlates with protracted rod degeneration.

Fig. 3

Open in a new tab

PRLΔE1 expression is absent in acute light-induced RD in RHO-T4R retinas 24 h and 2 weeks after light-induced damage but is observed in the more slowly degenerating PDE6β-RCD1 retina (age: 14 weeks). A1, B1, C1 Retinal nuclear layers identified by Hoechst staining. A2, B2, C2 TUNEL staining. A3, B3, C3 PRL-ISH. A4, B4, C4 Merged images show nuclei in blue, TUNEL staining in green, and PRLΔE1 in white. Retinas from one RHO-T4R dog for each time point and one PDE6β-RCD1 dog were examined. ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell layer.

To further explore the dynamics of PRLΔE1 expression in the RHO-T4R light-sensitive dog, we assessed its levels following exposure to two different light exposure intensities (0.5 mW/cm2 and 0.3 mW/cm2 for 1 min). These lower light intensities result in fewer TUNEL-labeled cells at 24 h post exposure and a greater survival of PRs at the two-week mark, though cell death is ongoing [39]. Nonetheless, PRLΔE1 was not expressed in the PRs at any time point under these conditions (Supplementary Fig. 3). Thus, our results suggest that PRLΔE1 expression is not associated with the acute rod cell death that can be experimentally triggered in this model but is instead linked to the chronic degenerative state observed in models with prolonged disease.

PRLΔE1 expression is suppressed in RPGR and NPHP5 mutant retinas after corrective gene augmentation therapy

Since we found that PRLΔE1 expression was restricted to unhealthy/diseased rods, we predicted that PRLΔE1 expression would be downregulated or abrogated if degeneration was halted, and PR homeostasis restored therapeutically. To test this hypothesis, we examined PRLΔE1 expression in two non-allelic diseases (RPGR-XLPRA and NPHP5-LCA) that have been previously successfully treated by AAV-mediated gene augmentation therapy [33, 41, 42]. Notably, in stark contrast to the high level of expression in untreated regions in retinas of the two RPGR-XLPRA models (XLPRA1 and XLPRA2), PRLΔE1 was not expressed within the AAV-RPGR treated area (treated at 28 weeks and 5 weeks of age, assessed at 49 and 33 weeks post treatment, respectively) (Fig. 4A, B). Similarly, in the NPHP5-LCA retinas, PRLΔE1 expression was remarkably reduced within the AAV-NPHP5 treated (at 6 weeks of age) retinal area when assessed 27 weeks post treatment, compared to the untreated retina (Fig. 4C, D). As expression of PRLΔE1 is associated with rod disease in the protracted phase of IRDs and can be suppressed by restoring PR to normal state following gene therapy, it raised the intriguing possibility that PRLΔE1 itself could be contributing to disease.

Fig. 4. Specific corrective gene augmentation therapy is associated with suppression of PRLΔE1 expression in treated areas.

Fig. 4

Open in a new tab

A1–A3 PRLΔE1 RNA-ISH in a RPGR-XLPRA1 dog (treated at 28 weeks of age, assessed 49 weeks post-treatment) shows PRLΔE1 expression in the untreated retina (A1) but the transcript is not expressed in AAV-RPGR treated area (A3). B1–B3 PRLΔE1 RNA-ISH in a RPGR-XLPRA2 (treated at 5 weeks of age, assessed 33 weeks post-treatment) dogs shows PRLΔE1 expression in the untreated retina (B1) but none in the AAV-RPGR treated area (B3). A2, B2 Transition zone presents a clear demarcation in PRLΔE1 expression between treated and untreated regions. PRLΔE1 RNA-ISH: White punctate staining; RPGR immunostaining in green. C1–C2, D1–D2 PRLΔE1 RNA-ISH in a NPHP5-LCA dog (treated at 6 weeks of age, assessed 27 weeks post-treatment) shows abundant PRLΔE1 in the ONL of the untreated area (C1, D1) but markedly reduced levels in the AAV-NPHP5 treated region (C2, D2). PRLΔE1 and NPHP5 RNA-ISH in pink (Fast Red) and green (HRP-Green) staining, respectively in (C1) and (C2) observed by brightfield microscopy. Only Fast Red dye, and thus PRLΔE1 RNA-ISH, staining is observed by fluorescence microscopy (D1, D2) in the same regions as panel (C). E Schematic representation of the en face fundus image of the retina, dotted line corresponds to the area of treatment (bleb) injected with a corrective gene therapy AAV vector. A single retina for each specified genotype was examined. ONL outer nuclear layer, INL inner nuclear layer.

Knockdown of PRLΔE1 expression confers transient protection to photoreceptors

To determine if PRLΔE1 expression is a cause or an effect of the disease process, we used RNA interference to knock down PRLΔE1 expression in PDE6β-RCD1 and RPGR-XLPRA2 retinas. Three different PRLΔE1-targeting shRNAs driven by the ubiquitous H1 promoter were tested in vitro in HEK293 cells co-transfected with a plasmid expressing PRLΔE1 (Supplementary Fig. 4). The shRNA showing the highest efficacy (shRNA2, ~70% knockdown) was selected for packaging in AAV2/5 vector for sustained expression after subretinal delivery in canine retinas. AAV2/5-shRNAPRLΔE1 was delivered subretinally in one PDE6β-RCD1 (age: 5 weeks) and two RPGR-XLPRA2 (age: 7 weeks) dogs at ages corresponding to the early acute phase of cell death and start of PRLΔE1 expression in surviving PRs in these models [23–25].

To assess the impact of shRNA-mediated PRLΔE1 knockdown on retinal structure and gene expression, we used in vivo imaging and histochemical analysis at two time points. Confocal scanning laser ophthalmoscopy and spectral domain optical coherence tomography (cSLO/OCT) were utilized to monitor retinal structure. In normal retinas, a hyporeflective layer corresponding to the ONL was evident in cross-sectional cSLO/OCT images (Fig. 5A). Quantitative ONL thickness maps were generated across wide expanses of the retina. These maps revealed preserved ONL in the treated areas for all three dogs at 5 weeks post injection (PI) (Fig. 5B, C1, D1). The ONL was thicker in the treated regions, clearly demarcated from untreated areas both on topographic representation as well as on representative cross-sections (Fig. 5B, C1, D1). However, we noted a thinning of the inner segment/outer segment (IS/OS or EZ) layer within the treated areas. One RPGR-XLPRA2 dog was terminated at this point for structural/expression analysis. For extended evaluation, cSLO/OCT imaging was continued up to 9 weeks PI in the PDE6β-RCD1 dog and up to 11 weeks PI in the remaining RPGR-XLPRA2 dog. Over time, there appeared to be progressive thinning of the ONL layer both in treated and untreated areas (Fig. 5C2, D2), prompting termination of the study at these time points.

Fig. 5. In vivo assessment of ONL thickness after treatment with shRNAPRLΔE1 in PDE6β-RCD1 and RPGR-XLPRA2 retinas.

Fig. 5

Open in a new tab

A–D2 Topographical pseudocolor maps (left) and reconstituted horizontal b-scans spanning through (red arrow) the treated (Tx) and untreated (Un-Tx) retinal areas (right) of a normal untreated retina (A), two RPGR-XLPRA2 treated retinas (B, C1–C2), and a PDE6β-RCD1 treated retina (D1–D2). Dashed lines on maps (left) encircle the area of the subretinal bleb, dashed vertical lines on b-scans (right) demarcate the transition between Tx and Un-Tx. ONL layer thickness on b-scans is highlighted in blue. Calibration bars and pseudocolor scale shown in (A) are applicable to all panels.

Quantitative-PCR analysis showed approximately 80% knockdown at 5-weeks PI and nearly 95% reduction in PRLΔE1 mRNA at 11-weeks PI in the shRNA treated area in the two RPGR-XLPRA2 dogs (Fig. 6A). This reduction was confirmed by RNA-ISH in the PDE6β-RCD1 dog (Fig. 6B). Immunohistochemistry performed in the RPGR-XLPRA2 dog terminated at 5 weeks PI confirmed that the ONL was thicker in the shRNA-treated area compared to the untreated areas. PRL-ISH indicated a qualitative reduction in PRLΔE1 expression in the treated area where the ONL thickness was maintained. However, knockdown of PRLΔE1 was associated with a shortening of IS and OS and did not correct opsin mislocalization in rods. Surprisingly, in the dogs treated for longer duration, we noted a loss of arrestin-3 (ARR3) staining, a marker of cone PRs, within the treated area, suggesting that PRLΔE1 knockdown caused a loss of cone cell viability (Fig. 7C, D). Thus, while shRNAPRLΔE1 mediated PRLΔE1 knockdown was protective at first, its longer-term protection was compromised by an unexpected loss of cones in treated retinas.

Fig. 6. Assessment of AAV2/5- shRNAPRLΔE1-mediated PRLΔE1 knockdown and effect on photoreceptors.

Fig. 6

Open in a new tab

A1 Percentage of PRLΔE1 remaining as quantified by qPCR in RPGR-XLPRA2 retinas 5 weeks and 11 weeks post injection (PI). A2 Schematic representation of RPGR-XLPRA2 retinas with treated area demarcated by dotted lines and 3 mm retinal punches used for qPCR analysis shown with green (treated area) or red (untreated area) circles. Representative RNA-ISH (magenta dots, arrows) image showing PRLΔE1 expression in ONL of untreated (B1) and shRNAPRLΔE1-treated (B2) retinal areas in PDE6β-RCD1. C1–D4 Immunohistochemical staining for rods (Rhodopsin, RHO, green) and cones (Arrestin-3, ARR3, red) with PRLΔE1-ISH (white) in untreated (C1–C4) and treated (D1–D4) regions of a RPGR-XLPRA2 retina 5-weeks PI. E1–F2 Immunohistochemical staining for rods (Rhodopsin, RHO, green) and cones (Arrestin-3, ARR3, red) with PRLΔE1-ISH (white) in untreated (E1–E2) and, treated (F1–F2) regions of a PDE6β-RCD1 retina 9 weeks PI. Note: Only PRLΔE1 and ARR3 are shown in (E2) and (F2) to emphasize the loss of cones in the retina following the shRNA treatment. Data presented is from one PDE6β-RCD1 and 2 RPGR-XLPRA2 dogs treated with shRNAPRLΔE1. ONL outer nuclear layer, INL, inner nuclear layer, GCL ganglion cell layer.

Fig. 7. Effect of subretinal injection of AAV2/5-shRNAPRLΔE1 in normal dog retina.

Fig. 7

Open in a new tab

A cSLO en face image and OCT b-scan of the retina showing the treated (Tx) and the untreated (UnTx) areas. B1–C4 Immunohistochemical staining of rods (RHO, green) and cones (ARR3, red) in untreated (B1–B4) and treated (C1–C4) retinal areas 8 weeks post injection. Mislocalization of Rhodopsin (RHO) protein to the cell bodies (C2) and loss of cone specific Arrestin-3 (ARR3) staining (C3) is observed in the treated retina. OS outer segment layer, IS inner segment layer, ONL outer nuclear layer, INL inner nuclear layer.

PRLΔE1 shRNA has a potential non-specific toxic effect that is detrimental to photoreceptor survival

Since cones do not express PRLΔE1, we hypothesized that cone cell death following shRNA treatment was due to either the loss of PRLΔE1 in the diseased rods, or a non-specific effect of this particular shRNAPRLΔE1. To distinguish between these two possibilities, we subretinally injected a normal adult dog with AAV2/5-shRNAPRLΔE1 at the same dose used in the mutant dogs. We presumed that since rods in the normal retina do not express PRLΔE1, shRNA injection would have no effect. However, at 8 weeks PI, we observed a disruption in the ONL and loss of the IS/OS line by in vivo OCT imaging, as seen in the mutants (Fig. 7A). After termination, we also observed mislocalization of rod opsin and loss of cones (Fig. 7B, C). These results suggest that the cone cell death observed in the normal and mutant retinas after shRNA treatment is not due to silencing of PRLΔE1 in rods but is instead due to a non-specific toxic effect of our current shRNA. As PRLΔE1 knockdown early after injection preserved the ONL, future studies are warranted to determine if therapeutic targeting of PRLΔE1 has the potential to be protective in multiple forms of IRD when implemented with an improved gene silencing strategy.

Discussion

A defining feature of most IRDs is that despite being genetically identical, PRs do not die at the same time. Instead, as is observed in many animal models of RD [24, 25, 43, 44], there is a surge in PR cell death in the early stages of disease followed by a protracted phase of PR cell loss that provides a potential window for therapeutic intervention. Notably, this initial burst of cell death also promotes transcriptional changes in the surviving PRs that leads to upregulation of both pro-survival and pro-inflammatory molecules [24, 45–47], the balance of which may determine the fate of each PR in the later phase of degeneration. To identify factors that impact PR survival during the protracted phase of disease, we analyzed retinal transcripts and pathways that are altered in two early onset canine diseases, PDE6β-RCD1 and RPGR-XLPRA2, when more than 50% of the PRs are lost [46]. One of the top upregulated transcripts in both diseases was PRL [46] which we subsequently showed to be the novel PRLΔE1 isoform [23]. Furthermore, our previous studies showed that neither the full-length PRL nor the short isoform is expressed in normal retinas (Sudharsan et al. [23], Supplementary Fig. 1) [23].

In the current study, PRLΔE1 was consistently upregulated in rods during chronic stages of disease progression across several IRDs. This expression pattern implies that PRLΔE1 may play a role in the cellular response to prolonged stress and degeneration rather than being a direct mediator of cell death. The early preservation of ONL following PRLΔE1 knockdown further supports the notion that PRLΔE1 is not merely a byproduct of degeneration but may actively contribute to the progression of the disease. Its expression during the chronic phase of degeneration hints at a role in sustaining or exacerbating the degenerative process, potentially through mechanisms related to cellular stress responses or inflammatory pathways. Understanding the exact function of PRLΔE1 in these contexts could provide valuable insights into its potential as a therapeutic target for IRDs.

While the precise modifications and transcription factors involved in PRLΔE1 expression are currently under investigation, alternative Transcription Start Sites (aTSS) have been identified in 52% of human protein-coding genes [48]. Along with alternative splicing, aTSS significantly increase transcriptomic diversity, allowing for dynamic fine-tuning of the cellular transcriptome in response to various physiological and pathological stimuli [49–55]. Epigenetic alterations such as DNA methylation and histone acetylation/deacetylation are common to many neurodegenerative diseases, including IRDs, and change the chromosomal accessibility to direct transcription from aTSS [56–58]. We speculate that these epigenetic changes in IRDs may also direct the choice of aTSS in the PRL gene, thus inducing and upregulating PRLΔE1 as disease progresses.

While we had previously found that PRLΔE1 expression was associated with disease, it remained to be determined if it played an active role in IRD or its expression was a consequence of the disease process. Our PRLΔE1 knockdown studies support a role for this transcript in promoting disease in the retina. This is in contrast with the anti-apoptotic role identified for the full length PRL in retina [10, 13], and the neurogenic and neuroprotective roles in the CNS [59]. Given the limitations of our currently used shRNAPRLΔE1 with demonstrated off-target effects even in normal retinas, we could not address in the present study the long-term effects that silencing PRLΔE1 expression may have on PR preservation. Efforts to develop a PRLΔE1 targeting shRNA without off target /non-specific deleterious effects are ongoing.

It is currently unclear whether PRLΔE1 exerts its effect as RNA or protein. In our earlier publication [23], we showed that very small amounts of PRL protein could be identified in extracts from PDE6β-RCD1 and RPGR-XLPRA2 retinas using mass spectrometry. However, the low protein abundance and resulting poor peptide coverage precluded identification of the complete PRLΔE1 protein sequence. PRLΔE1 mRNA lacks a consensus Kozak sequence [60] at the first in-frame AUG codon, potentially explaining the extremely low levels of PRLΔE1 protein in extracts from mutant retinas. However, the protein structure prediction algorithm I-TASSER [61, 62] estimates that the short protein isoform can form a 4 helix bundle similar to the full length PRL, and we predict that, if expressed, the protein should be able to bind the PRL receptor, albeit with lower affinity [23].

As PRLΔE1 protein was present at extremely low levels if present at all, it is also worth considering the potential role of PRLΔE1 mRNA as a regulatory non-coding RNA. Long non-coding RNAs (lncRNA) are abundantly expressed in CNS and neuroretina, have important roles in normal physiology and homeostasis, and are implicated in pathophysiology of neurodegenerative disorders including Alzheimer’s and Parkinson’s diseases, as well as in retinal degenerations [63–67]. Transcripts longer than 500 nucleotides (earlier definition included transcripts >200 nt) [68] can be considered lncRNAs and at >850 nt, PRLΔE1 transcripts satisfy this first criterion. The second criterion for a transcript to be designated ncRNA is the exclusion of the defining characteristics of protein coding loci. However, as shown recently for many other lncRNAs [68], the PRLΔE1 transcript exhibits most attributes of mRNAs. As we cannot currently rule out the potential for this transcript to have both protein coding and regulatory functions [68, 69], our ongoing studies are aimed at defining the active PRLΔE1 entity.

We acknowledge two limitations in this study: the small number of dogs in which ONL rescue was demonstrated by PRLΔE1 silencing and the lack of elucidation of the biological pathways through which PRLΔE1 may drive rod degeneration and loss. We intentionally limited the number of dogs recruited for this study after we observed off-target effects with the currently used shRNA. Further, PRLΔE1 isoform is not expressed in the rodent retinas [23], making dogs affected with IRDs valuable animal models in which the function of PRLΔE1 can be investigated. Future studies employing more specific knockdown of this isoform will aim to identify the pathways that are activated by PRLΔE1 in mutant retinas, and explore the translational potential of modulating its expression.

In summary, examination of PRLΔE1 mRNA expression in four different forms of canine IRD with different degeneration paradigms reveals its consistent expression in IRDs, regardless of the causative gene mutation. Moreover, a causative role for PRLΔE1 mRNA in disease progression is supported by our findings that expression is suppressed when disease progression is halted by corrective gene-specific therapy and that PRLΔE1 knockdown in at least two models of IRD has an initial protective effect on the PRs. Together, our findings suggest that PRLΔE1 knockdown/silencing represents an exciting novel “gene agnostic” therapeutic strategy for IRD. Future studies will include assessing the long-term outcome of PRLΔE1 knockdown on preservation of PRs and identification of the specific pathways through which PRLΔE1 modulates PR survival.

Materials and methods

Animal use statement

The studies adhered to the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. All dogs were bred and maintained under standard care conditions (diet, ambient illumination with cyclic 12 h ON-12 h OFF light) at the Retinal Disease Studies Facility (RDSF) of the University of Pennsylvania. In compliance with the 3 R guiding principle, most studies were carried out on archival tissue sections from dogs that were previously used in other studies. All dogs used are listed in Supplementary Table 1.

In vitro PRLΔE1 shRNA screening

Three shRNA constructs driven by the H1-promoter and targeting different regions of the PRLΔE1 were screened in vitro in HEK293 cells overexpressing the PRLΔE1-mCherry reporter gene. Briefly, HEK293 cells were seeded in 12 well plates and co-transfected the following day at 70–90% confluence with the PRLΔE1-mCherry plasmid and one of the three PRLΔE1-targetting shRNAs, or a non-specific shRNA. Transfections were performed in triplicates using Lipofectamine 2000. The cells were incubated for 24 h at 37 °C in a 5% CO2 with room air incubator. Following incubation, the cells were collected, total RNA extracted using the Qiagen RNeasy Plus Mini kit and reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, ThermoFisher Scientific). qPCR analysis was performed using PowerUp SYBR Green Mastermix (Applied Biosystems, ThermoFisher Scientific) in either Applied Biosystems 7500 Real Time PCR System or Applied Biosystems ViiA 7 Real Time PCR System in a 96-well or 384-well format.

Subretinal AAV-shRNAPRLΔE1 injections

The most efficient shRNA identified by in vitro screening was packaged in AAV2/5 (Ocular Gene Therapy Core, University of Florida, Gainesville, FL) and delivered subretinally in the superotemporal quadrant using a 25/38 G PolyTip cannula (MedOne® Sarasota, FL, U.S.A.) attached to a 1 mL Luer-Lok™ syringe (Beckton, Dickinson and Company, NJ, U.S.A.) in dogs under general anesthesia. Injections were performed using a Stellaris PC injection system (Bausch and Lomb, Rochester, NY, USA) and visualized through a Zeiss operating microscope (Carl Zeiss Meditec, Inc., Dublin, CA, U.S.A.) with the image projected on a NGenuity® 3D screen (Alcon, Geneva, Switzerland). Optimal dose of AAV2/5-shRNAPRLΔE1 was determined in a pilot study by subretinally injecting 150 µL of two different doses (5 × 1011 and 5 × 1012 vg/mL) of the vector in each eye of one RPGR-XLPRA2 dog (age ~40 weeks) when ample PRLΔE1 expression in the PRs is observed. Subsequently, AAV2/5-shRNAPRLΔE1 was delivered at a dose of 5 × 1012 vg/mL in one PDE6β-RCD1 (age: 5 weeks) and two RPGR-XLPRA2 (age: 7 weeks) dogs (subretinal, volume: 70 µLs), and in one normal adult (age: 4.5 years) dog (subretinal, volume: 150 µLs).

In vivo retinal imaging

Confocal scanning laser ophthalmoscopy and spectral domain optical coherence tomography (cSLO/OCT) was performed for in vivo retinal assessment (HRA + OCT Spectralis®, Heidelberg Engineering Inc, MA, USA). Autofluorescence cSLO images were taken using a 130° field-of-view lens, and 55° infra-red and blue-light. Sequential OCT scans of the bleb and bleb-adjacent areas were obtained to check for retinal changes over time. Further post-acquisition processing of cSLO/OCT data was performed with custom programs (MATLAB; MathWorks, Natick, MA, USA) as previously described [42, 70]. For retina-wide topographic analysis, integrated backscatter intensity of each raster scan was used to locate its precise location and orientation relative to retinal features visible on cSLO images. Individual longitudinal reflectivity profiles (LRPs) forming all registered raster scans were allotted to regularly spaced bins (1° × 1°) in a rectangular coordinate system centered at the optic nerve; LRPs in each bin were aligned and averaged. Intraretinal peaks and boundaries corresponding to the ONL were segmented using both intensity and slope information of backscatter signal along each LRP. For all topographic results, locations of blood vessels, optic nerve head, and bleb boundaries were overlaid for reference.

Ocular tissue collection

Ocular tissues were collected after euthanasia with intravenous sodium pentobarbital injection. After enucleation, 3 mm diameter retinal punches were obtained within and outside the area injection bleb. The posterior eyecup was fixed at 4 °C in 4% paraformaldehyde (PFA) for 3 h, followed by 2% PFA for 24 h. Tissues were dissected, cryopreserved by sequential 24 h steps in 15% and 30% sucrose-PBS solutions, and then embedded in Optimal Cutting Temperature (OCT) medium.

RNA in situ hybridization, immunohistochemistry, and TUNEL Assay

PRLΔE1 mRNA was visualized by RNA-in situ hybridization (RNA-ISH) using the RNAscope assay 2.5 HD Assay-Red (Advanced Cell Diagnostics, ACD-Bio, BioTechne, Newark, CA, USA) as described previously [23]. Briefly, 10 µm thick sections were cut from PFA-fixed OCT-embedded canine retinas. Target retrieval was performed by heating the slides at 88 °C for 10 min in Target Retrieval buffer, followed by 15 min of protease treatment. PRLΔE1 probe (RNAscope cat no. 535781) binding and visualization were performed as described in the kit protocol. Slides were then either counterstained with hematoxylin or used for immunohistochemistry/TUNEL assay. RNAscope 2.5 HD Duplex Assay was performed following kit recommendations for co-visualization of PRLΔE1 and NPHP5 (RNAscope probe cat no. 462841) RNAs. PRLΔE1 was visualized using Fast Red dye and NPHP5 was stained with HRP-Green.

When performing dual staining with RNA-ISH and immunohistochemistry (IHC), the retinal sections were treated with a blocking buffer for 1 h (5% BSA and 4.5% fish gelatin in PBS) immediately following RNA-ISH, and then incubated overnight with the primary antibodies (RHO, Millipore MAB5316, 1:200; ARR3, C.Craft, Univ. of Southern California, LUMIF; RPGR, Sigma HPA001593, 1:100) at 4 °C. Antigen antibody complexes were visualized with Alexa-stained secondary antibodies. Hoechst 33342 stain (Thermo Fisher Scientific) was used to label cell nuclei. TUNEL assay was performed to assess cell death in the retinal sections as previously reported [39]. Slides were mounted in Gelvatol mounting medium and examined with an epifluorescence microscope (Axioplan, Carl Zeiss Meditec). Images were captured with the Axiocam 305 camera and Zeiss Zen Microscopy software and processed using the Adobe Photoshop and Illustrator programs for display.

Supplementary information

Supplementary Material (3.7MB, pdf)

Acknowledgements

We thank Svetlana Savina for help with histology and imaging, the staff at RDSF for animal care support and coordinating in vivo studies, and Lydia Melnyk for research coordination.

Author contributions

Experimental design: RS and WAB; Investigation: RS, JK, WAB.; Data analysis: RS, JK, MS, AS, AVC, WAB; Writing: RS; Editing: GDA, AVC, WAB; Reviewing: all co-authors; Funding acquisition: RS, GDA, WAB Corresponding authors: RS. and WAB.

Funding

This work was supported by grants from NIH (RO1-EY006855, RO1-EY017549, P30-EY001583), the Foundation Fighting Blindness, McCabe Fund Pilot Grant, S.G. Jacobson MD PhD Memorial Fund, unrestricted funds from RPB, and the University Research Foundation grant from the University of Pennsylvania.

Data availability

All experimental data related to this study are included in the published article and supplementary materials. Any additional supporting data will be available from the corresponding authors upon request and shared on Dryad.

Competing interests

RS and WAB have a provisional patent filed by the University of Pennsylvania on “Modulation of PRLΔE1 expression for the treatment of inherited retinal degenerations” The other authors declare no competing financial interests.

Ethics approval and consent to participate

All methods were performed in accordance with the relevant guidelines and regulations. The animal studies adhered to the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

Footnotes

Edited by Massimiliano Agostini

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

6/20/2025

In this article the Funding section has been updated.

Contributor Information

Raghavi Sudharsan, Email: raghavi@vet.upenn.edu.

William A. Beltran, Email: wbeltran@vet.upenn.edu

Supplementary information

The online version contains supplementary material available at 10.1038/s41419-024-07070-1.

References

  • 1.Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110–6. [DOI] [PubMed] [Google Scholar]
  • 2.Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15:356–65. [DOI] [PubMed] [Google Scholar]
  • 3.Triebel J, Bertsch T, Bollheimer C, Rios-Barrera D, Pearce CF, Hufner M, et al. Principles of the prolactin/vasoinhibin axis. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1193–203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Costanza M, Binart N, Steinman L, Pedotti R. Prolactin: a versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev. 2015;14:223–30. [DOI] [PubMed] [Google Scholar]
  • 5.Triebel J, Bertsch T, Clapp C. Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited. Front Endocrinol. 2022;13:994898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Torner L. Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology. Front Endocrinol. 2016;7:25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19:225–68. [DOI] [PubMed] [Google Scholar]
  • 8.O’Steen WK, Kraeer SL. Effects of hypophysectomy, pituitary gland homogenates and transplants, and prolactin on photoreceptor destruction. Investig Ophthalmol Vis Sci. 1977;16:940–6. [PubMed] [Google Scholar]
  • 9.Arnold E, Rivera JC, Thebault S, Moreno-Paramo D, Quiroz-Mercado H, Quintanar-Stephano A, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010;59:3192–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Arnold E, Thebault S, Baeza-Cruz G, Arredondo Zamarripa D, Adan N, Quintanar-Stephano A, et al. The hormone prolactin is a novel, endogenous trophic factor able to regulate reactive glia and to limit retinal degeneration. J Neurosci. 2014;34:1868–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Triebel J, Macotela Y, de la Escalera GM, Clapp C. Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy. IUBMB Life. 2011;63:806–10. [DOI] [PubMed] [Google Scholar]
  • 12.Froland A, Hagen C, Lauritzen E. Diabetic retinopathy and prolactin. Lancet. 1977;1:45. [DOI] [PubMed] [Google Scholar]
  • 13.Melendez Garcia R, Arredondo Zamarripa D, Arnold E, Ruiz-Herrera X, Noguez Imm R, Baeza Cruz G, et al. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine. 2016;7:35–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Thebault S. Potential mechanisms behind the antioxidant actions of prolactin in the retina. Exp Eye Res. 2017;160:56–61. [DOI] [PubMed] [Google Scholar]
  • 15.Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, Lopez-Barrera F, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci. 2005;46:2947–53. [DOI] [PubMed] [Google Scholar]
  • 16.Clapp C, Thebault S, Macotela Y, Moreno-Carranza B, Triebel J, Martinez de la Escalera G. Regulation of blood vessels by prolactin and vasoinhibins. Adv Exp Med Biol. 2015;846:83–95. [DOI] [PubMed] [Google Scholar]
  • 17.Diaz-Lezama N, Wu Z, Adan-Castro E, Arnold E, Vazquez-Membrillo M, Arredondo-Zamarripa D, et al. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Invest. 2016;96:283–95. [DOI] [PubMed] [Google Scholar]
  • 18.Robles-Osorio ML, Garcia-Franco R, Nunez-Amaro CD, Mira-Lorenzo X, Ramirez-Neria P, Hernandez W, et al. Basis and design of a randomized clinical trial to evaluate the effect of levosulpiride on retinal alterations in patients with diabetic retinopathy and diabetic macular edema. Front Endocrinol. 2018;9:242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639–69. [DOI] [PubMed] [Google Scholar]
  • 20.Marano RJ, Ben-Jonathan N. Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol. 2014;28:622–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Rivera JC, Aranda J, Riesgo J, Nava G, Thebault S, Lopez-Barrera F, et al. Expression and cellular localization of prolactin and the prolactin receptor in mammalian retina. Exp Eye Res. 2008;86:314–21. [DOI] [PubMed] [Google Scholar]
  • 22.Garza-Rodriguez ML, Rodriguez-Sanchez IP, Gonzalez-Alvarez R, Luna M, Burciaga-Flores CH, Alcorta-Nunez F, et al. Prolactin expression in the baboon (Papio hamadryas) eye. Animals. 2022;12:2288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sudharsan R, Murgiano L, Tang HY, Olsen TW, Chavali VRM, Aguirre GD, et al. Short prolactin isoforms are expressed in photoreceptors of canine retinas undergoing retinal degeneration. Sci Rep. 2021;11:460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Beltran WA, Hammond P, Acland GM, Aguirre GD. A frameshift mutation in RPGR exon ORF15 causes photoreceptor degeneration and inner retina remodeling in a model of X-linked retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2006;47:1669–81. [DOI] [PubMed] [Google Scholar]
  • 25.Genini S, Beltran WA, Aguirre GD. Up-regulation of tumor necrosis factor superfamily genes in early phases of photoreceptor degeneration. PLoS ONE. 2013;8:e85408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ray K, Baldwin VJ, Acland GM, Blanton SH, Aguirre GD. Cosegregation of codon 807 mutation of the canine rod cGMP phosphodiesterase beta gene and rcd1. Investig Ophthalmol Vis Sci. 1994;35:4291–9. [PubMed] [Google Scholar]
  • 27.Suber ML, Pittler SJ, Qin N, Wright GC, Holcombe V, Lee RH, et al. Irish setter dogs affected with rod/cone dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase beta-subunit gene. Proc Natl Acad Sci USA. 1993;90:3968–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Aguirre GD, Rubin LF. Rod-cone dysplasia (progressive retinal atrophy) in Irish setters. J Am Vet Med Assoc. 1975;166:157–64. [PubMed] [Google Scholar]
  • 29.Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S, Tulloch B, et al. Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. Hum Mol Genet. 2002;11:993–1003. [DOI] [PubMed] [Google Scholar]
  • 30.Zeiss CJ, Acland GM, Aguirre GD. Retinal pathology of canine X-linked progressive retinal atrophy, the locus homologue of RP3. Investig Ophthalmol Vis Sci. 1999;40:3292–304. [PubMed] [Google Scholar]
  • 31.Downs LM, Scott EM, Cideciyan AV, Iwabe S, Dufour V, Gardiner KL, et al. Overlap of abnormal photoreceptor development and progressive degeneration in Leber congenital amaurosis caused by NPHP5 mutation. Hum Mol Genet. 2016;25:4211–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Goldstein O, Mezey JG, Schweitzer PA, Boyko AR, Gao C, Bustamante CD, et al. IQCB1 and PDE6B mutations cause similar early onset retinal degenerations in two closely related terrier dog breeds. Investig Ophthalmol Vis Sci. 2013;54:7005–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Beltran WA, Cideciyan AV, Lewin AS, Iwabe S, Khanna H, Sumaroka A, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA. 2012;109:2132–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Sidjanin DJ, Lowe JK, McElwee JL, Milne BS, Phippen TM, Sargan DR, et al. Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. Hum Mol Genet. 2002;11:1823–33. [DOI] [PubMed] [Google Scholar]
  • 35.Yeh CY, Goldstein O, Kukekova AV, Holley D, Knollinger AM, Huson HJ, et al. Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. BMC Genet. 2013;14:27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Beltran WA, Acland GM, Aguirre GD. Age-dependent disease expression determines remodeling of the retinal mosaic in carriers of RPGR exon ORF15 mutations. Investig Ophthalmol Vis Sci. 2009;50:3985–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kijas JW, Cideciyan AV, Aleman TS, Pianta MJ, Pearce-Kelling SE, Miller BJ, et al. Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa. Proc Natl Acad Sci USA. 2002;99:6328–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling SE, Sumaroka A, et al. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci USA. 2005;102:5233–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Sudharsan R, Simone KM, Anderson NP, Aguirre GD, Beltran WA. Acute and protracted cell death in light-induced retinal degeneration in the canine model of rhodopsin autosomal dominant retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2017;58:270–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Marsili S, Genini S, Sudharsan R, Gingrich J, Aguirre GD, Beltran WA. Exclusion of the unfolded protein response in light-induced retinal degeneration in the canine T4R RHO model of autosomal dominant retinitis pigmentosa. PLoS ONE. 2015;10:e0115723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Beltran WA, Cideciyan AV, Iwabe S, Swider M, Kosyk MS, McDaid K, et al. Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci USA. 2015;112:E5844–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Aguirre GD, Cideciyan AV, Dufour VL, Ripolles-Garcia A, Sudharsan R, Swider M, et al. Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis. Mol Ther. 2021;29:2456–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Arango-Gonzalez B, Trifunovic D, Sahaboglu A, Kranz K, Michalakis S, Farinelli P, et al. Identification of a common non-apoptotic cell death mechanism in hereditary retinal degeneration. PLoS ONE. 2014;9:e112142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.LaVail MM, Nishikawa S, Steinberg RH, Naash MI, Duncan JL, Trautmann N, et al. Phenotypic characterization of P23H and S334ter rhodopsin transgenic rat models of inherited retinal degeneration. Exp Eye Res. 2018;167:56–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Samardzija M, Wariwoda H, Imsand C, Huber P, Heynen SR, Gubler A, et al. Activation of survival pathways in the degenerating retina of rd10 mice. Exp Eye Res. 2012;99:17–26. [DOI] [PubMed] [Google Scholar]
  • 46.Sudharsan R, Beiting DP, Aguirre GD, Beltran WA. Involvement of innate immune system in late stages of inherited photoreceptor degeneration. Sci Rep. 2017;7:17897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:100–5. [DOI] [PubMed] [Google Scholar]
  • 48.Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006;16:55–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Pal S, Gupta R, Kim H, Wickramasinghe P, Baubet V, Showe LC, et al. Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development. Genome Res. 2011;21:1260–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Popova EY, Salzberg AC, Yang C, Zhang SS, Barnstable CJ. Identification and prediction of alternative transcription start sites that generate rod photoreceptor-specific transcripts from ubiquitously expressed genes. PLoS ONE. 2017;12:e0179230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Roni V, Carpio R, Wissinger B. Mapping of transcription start sites of human retina expressed genes. BMC Genom. 2007;8:42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Zhang X, Chen MH, Wu X, Kodani A, Fan J, Doan R, et al. Cell-type-specific alternative splicing governs cell fate in the developing cerebral cortex. Cell. 2016;166:1147–62.e15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Makhnovskii PA, Gusev OA, Bokov RO, Gazizova GR, Vepkhvadze TF, Lysenko EA, et al. Alternative transcription start sites contribute to acute-stress-induced transcriptome response in human skeletal muscle. Hum Genom. 2022;16:24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Mao P, Shen Y, Mao X, Liu K, Zhong J. The single-cell landscape of alternative transcription start sites of diabetic retina. Exp Eye Res. 2023;233:109520. [DOI] [PubMed] [Google Scholar]
  • 55.Thorsen K, Schepeler T, Oster B, Rasmussen MH, Vang S, Wang K, et al. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genom. 2011;12:505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Lu H, Liu X, Deng Y, Qing H. DNA methylation, a hand behind neurodegenerative diseases. Front Aging Neurosci. 2013;5:85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Miller AL, James RE, Harvey AR, Trifunovic D, Carvalho LS. The role of epigenetic changes in the pathology and treatment of inherited retinal diseases. Front Cell Dev Biol. 2023;11:1224078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Orozco LD, Owen LA, Hofmann J, Stockwell AD, Tao J, Haller S, et al. A systems biology approach uncovers novel disease mechanisms in age-related macular degeneration. Cell Genom. 2023;3:100302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Costanza M, Pedotti R. Prolactin: friend or foe in central nervous system autoimmune inflammation? Int J Mol Sci. 2016;17:2026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol. 1987;196:947–50. [DOI] [PubMed] [Google Scholar]
  • 61.Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5:725–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12:7–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Carrella S, Banfi S, Karali M. Sophisticated gene regulation for a complex physiological system: the role of non-coding RNAs in photoreceptor cells. Front Cell Dev Biol. 2020;8:629158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Salta E, De Strooper B. Noncoding RNAs in neurodegeneration. Nat Rev Neurosci. 2017;18:627–40. [DOI] [PubMed] [Google Scholar]
  • 65.Salvatori B, Biscarini S, Morlando M. Non-coding RNAs in nervous system development and disease. Front Cell Dev Biol. 2020;8:273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Shi X, Xue Z, Ye K, Yuan J, Zhang Y, Qu J, et al. Roles of non-coding RNAs in eye development and diseases. Wiley Interdiscip Rev RNA. 2023;14:e1785. [DOI] [PubMed] [Google Scholar]
  • 67.Song J, Kim YK. Targeting non-coding RNAs for the treatment of retinal diseases. Mol Ther Nucleic Acids. 2021;24:284–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24:430–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Li J, Liu C. Coding or noncoding, the converging concepts of RNAs. Front Genet. 2019;10:496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Dufour VL, Yu Y, Pan W, Ying GS, Aguirre GD, Beltran WA. In-vivo longitudinal changes in thickness of the postnatal canine retina. Exp Eye Res. 2020;192:107926. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material (3.7MB, pdf)

Data Availability Statement

All experimental data related to this study are included in the published article and supplementary materials. Any additional supporting data will be available from the corresponding authors upon request and shared on Dryad.

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES